Home/Pipeline/Daiichi Sankyo Collaboration

Daiichi Sankyo Collaboration

Oncology

DiscoveryActive

Key Facts

Indication

Oncology

Phase

Discovery

Status

Active

Company

General Proximity

About General Proximity

General Proximity is an early-stage biotech leveraging a proprietary proximity discovery engine, OmniTAC™, to create novel therapeutics that modulate protein function by controlling intracellular proximity events. The company has secured backing from leading technical investors and major grants, and has established a multi-target collaboration with Daiichi Sankyo in oncology. With a seasoned team from top academic and industry institutions, General Proximity is positioned to advance a pipeline of proximity medicines, though it remains pre-clinical and pre-revenue.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active